Neutropenia News - LARVOL Sigma

Neutropenia	Welcome, Profile Billing Logout

12 3 4 5 6 7 8 9 10 11 12 13...645 646 »

|||||||||| Livtencity (maribavir) / Takeda, GSK
Journal, Real-world evidence: Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using Lab-linked claims Data in the United States. (Pubmed Central) - Jun 6, 2025
P3
MBV's favorable benefit-risk profile makes it a potentially valuable addition to the CMV treatment armamentarium. www.clinicaltrials.gov identifier is NCT02931539.

|||||||||| Journal: The impact of renal dysfunction after critical illness on the management of cancer. (Pubmed Central) - Jun 6, 2025
Oxygen supplementation was needed. What impact did critical illness, more specifically renal dysfunction, have on the planning of onco-hematological treatment in this patient?

|||||||||| alvocidib (DSP-2033) / Sumitomo Pharma
Journal: Flavopiridol restores granulopoiesis in experimental models of severe congenital neutropenia. (Pubmed Central) - Jun 5, 2025
Flavopiridol also restored granulopoiesis caused by diminished CEBPA expression, a known defective signaling molecule in CN. Thus, we described for the first time a potential therapy for CN with flavopiridol that could be potentially used to treat patients with different types of neutropenia.

|||||||||| Journal: Clinical profile and treatment outcomes of acute lymphoblastic leukemia among children attending at the University of Gondar comprehensive specialized hospital and Tikur Anbessa Specialized Hospital in Ethiopia. (Pubmed Central) - Jun 5, 2025
A high mortality rate was observed among children with ALL, with significant risk factors including relapse, age over 10 years, elevated LDH levels, sepsis, low platelet counts, T-cell ALL, malaria infection, and induction failure. To improve survival rates, it is essential to address these factors by optimizing treatment regimens and minimizing delays in diagnosis and care delivery.

|||||||||| Journal, Real-world evidence: The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real-world study. (Pubmed Central) - Jun 5, 2025
The majority of these events were classified as grade 1-2. The combination of NAIC and adjuvant immunotherapy displays short survival benefits and has an acceptable safety profile, which may be an effective treatment strategy for LA-ESCC patients.

|||||||||| Biomarker, Retrospective data, Journal, Next-generation sequencing, BRCA Biomarker: Clinical usefulness of next-generation sequencing-based target gene sequencing in diagnosis of inherited bone marrow failure syndrome. (Pubmed Central) - Jun 5, 2025
Pathogenic variants were more frequently observed in patients with a specific medical history or changes in cytopenia, and in those with additional clinical features (cytogenetic abnormalities or non-severe AA). This study demonstrated the diagnostic usefulness of NGS-based target gene sequencing for pediatric and AYA patients with suspected genetic hematologic disorders, supporting the need for multicenter studies and standardized guideline development.

|||||||||| Journal: To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy. (Pubmed Central) - Jun 5, 2025
Current practices often prioritize timely transplant/CAR-T procedures but may need to be adjusted to account for CARV infections. Implementing strategies such as reduced-intensity conditioning, enhanced infection prevention measures, and antiviral therapy could significantly impact patient outcomes, particularly in preventing progression to LRTD and reducing the risk for fatal outcome.

|||||||||| Avastin (bevacizumab) / Roche
P3 data, Retrospective data, Review, Journal: PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis. (Pubmed Central) - Jun 5, 2025
P3
However, its higher incidence of AEs requires cautious attention. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.

|||||||||| Cyramza (ramucirumab) / Eli Lilly, Neulasta (pegfilgrastim) / Roche, docetaxel / Generic mfg.
Retrospective data, Journal: Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim. (Pubmed Central) - Jun 5, 2025
Despite prophylactic pegfilgrastim, BNC was correlated with LNC and might be predictive of FN. We should be careful of BNC even if it meets the criteria for starting DTX?+?RAM treatment.

|||||||||| Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Observational data, Retrospective data, Journal, Real-world evidence: Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. (Pubmed Central) - Jun 5, 2025
Grade 3/4 neutropenia/febrile neutropenia and infections were reported in 32.7% and 18.4% of patients, respectively. Overall, results were consistent with the established profile of D-VTd, and these real-world effectiveness and safety results support the frontline use of subcutaneous daratumumab plus VTd in transplant-eligible patients with NDMM.

|||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. (Pubmed Central) - Jun 5, 2025
Overall, results were consistent with the established profile of D-VTd, and these real-world effectiveness and safety results support the frontline use of subcutaneous daratumumab plus VTd in transplant-eligible patients with NDMM. The results of this study indicated that eligible ICC patients with clinically diagnosed LC, as determined by clinical and CT imaging findings, did not exhibit any apparent safety or efficacy disadvantage compared to those without LC.

|||||||||| Review, Journal: Gene therapy for inborn errors of immunity: current clinical progress. (Pubmed Central) - Jun 4, 2025
After the unexpected occurrence of oncogenesis associated with the initial retroviral vector designs, significant advances have led to successful gene therapy clinical trials for three forms of SCID, which demonstrated the safety and efficacy of this approach. Active preclinical and clinical studies are ongoing for diverse IEI, including chronic granulomatous disease, leukocyte adhesion deficiency, severe congenital neutropenia, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia and familial forms of hemophagocytic lymphohistiocytosis.

|||||||||| Journal: Improving UTI Diagnostics in Oncology: Reliability of Reflex Urine Culture in Immunosuppressed Neutropenic and Non-neutropenic Cancer Patients. (Pubmed Central) - Jun 4, 2025
Active preclinical and clinical studies are ongoing for diverse IEI, including chronic granulomatous disease, leukocyte adhesion deficiency, severe congenital neutropenia, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia and familial forms of hemophagocytic lymphohistiocytosis. Reflex urine culture protocols contingent upon a screening dipstick urinalysis are a safe and effective platform for diagnostic stewardship in patients with cancer including those with neutropenia.

|||||||||| Abecma (idecabtagene vicleucel) / BMS
FDA event, Journal: FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class Exposed, Relapsed or Refractory Multiple Myeloma. (Pubmed Central) - Jun 4, 2025
ODAC voted 8 to 3 that the benefit-risk for ide-cel was favorable for the proposed indication. This is the first FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for this indication.

|||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Xofigo (radium Ra-223 dichloride) / Bayer
Journal: Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (Pubmed Central) - Jun 4, 2025
PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis.

||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion:  LUPER: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (clinicaltrials.gov) -  Jun 4, 2025
P1/2, N=28, Completed,  Sponsor: Antonio Calles Blanco
Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis. Active, not recruiting --> Completed

|||||||||| dexamethasone / Generic mfg., tinurilimab (BAY1834942) / Bayer
P1 data, Journal: A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. (Pubmed Central) - Jun 4, 2025
P1
Active, not recruiting --> Completed Following study termination, the clinical development program for tinurilimab was discontinued permanently.

|||||||||| Review, Journal: Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005). (Pubmed Central) - Jun 4, 2025
If indicated, invasive aspergillosis should be considered and appropriate diagnostic tests initiated. Isavuconazole and voriconazole are recommended as first-line treatment, liposomal amphotericin B as an alternative.

|||||||||| Journal: SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy. (Pubmed Central) - Jun 4, 2025
No significant survival differences were found between COVID?+?and COVID?-?patients. Improved outcomes likely resulted from widespread vaccination, prophylaxis, early antiviral treatments, and the emergence of less virulent SARS-CoV-2 variants, reducing disease severity and mortality, allowing for better management of these patients.

|||||||||| Rituxan (rituximab) / Roche
Retrospective data, Journal: Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia. (Pubmed Central) - Jun 4, 2025
Sarcopenia may be a significant risk factor for FN, G4 NP, and reduced overall survival in patients with DLBCL receiving R-CHOP, and it may potentially diminish the protective effects of PEG-G-CSF. Predictive models for FN and G4 NP incorporating sarcopenia and other clinical factors may improve individualized treatment strategies, although further validation is needed.

|||||||||| Journal: Storage-related artefacts in equine blood result in a pseudo-inflammatory leukogram. (Pubmed Central) - Jun 4, 2025
In most conditions, leukocyte counts decreased by 48?h, but remained within reference intervals in blood stored up to 120?h. Storage-related leukocyte changes in blood stored under conditions mimicking ambulatory practice resulted in a pseudo-inflammatory leukogram, which could alter interpretation and patient management.

|||||||||| Retrospective data, Journal: Microbiological Profile and Predictors of Multidrug- Resistant Organisms among Cancer Patients Admitted with Bacteremia: A Retrospective Cohort Study in Jordan. (Pubmed Central) - Jun 4, 2025
The use of antibiotics within the past 90 days and hematologic malignancy were predictors of MDRO bacteremia. Further predictive models for MDRO bacteremia are needed to help guide the empiric antibiotic prescribing decisions.

|||||||||| paclitaxel / Generic mfg.
Clinical, Retrospective data, Review, Journal, HEOR: Comparative Effectiveness of Paclitaxel-Containing Regimens for Treatment of Triple-Negative Breast Cancer: A Network Meta-Analysis. (Pubmed Central) - Jun 4, 2025
Additionally, TCM may be associated with a higher ORR and a reduced risk of AEs. Further large-scale, high-quality studies are warranted to investigate the efficacy and safety of combining paclitaxel with targeted agents, platinum-based therapies, or TCM in the treatment of TNBC.

|||||||||| Noxafil (posaconazole) / Merck (MSD)
Retrospective data, Journal: Clinical characteristics and prognosis of chronic disseminated candidiasis in children with acute leukemia following chemotherapy: a multicenter clinical study (Pubmed Central) - Jun 4, 2025
CDC in children with AL after chemotherapy may be associated with prolonged neutropenia due to intensive chemotherapy. Combination antifungal regimens based on liposomal amphotericin B have a higher cure rate, while persistently high CRP levels and positive ?-D-glucan tests may indicate poor prognosis.

|||||||||| Retrospective data, Review, Journal, Adverse events: Whether traditional Chinese medicine injection can reduce adverse events in patients with cancer? A Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jun 4, 2025
TCMI can reduce adverse events of anticancer treatment and serve as an adjuvant therapy. It is necessary to strengthen the mechanism research of TCMI and carry out more large-scale, multi-center and well-designed clinical studies to evaluate the synergistic effects of TCMI in the future.

|||||||||| docetaxel / Generic mfg., cabazitaxel / Generic mfg.
Journal: Toxicities of taxane-based chemotherapy in prostate cancer. (Pubmed Central) - Jun 4, 2025
Despite the wide-ranging toxicities of taxanes, they remain a cornerstone in advanced PCa treatment. Preventing and managing severe neutropenia, febrile neutropenia, and QoL-impairing toxicities are essential for maintaining treatment continuity and achieving optimal outcomes.

|||||||||| Talzenna (talazoparib) / Pfizer, Lynparza (olaparib) / Merck (MSD), AstraZeneca, Zejula (niraparib) / GSK, J&J
Journal: Toxicities of PARP inhibitors in genitourinary cancers. (Pubmed Central) - Jun 4, 2025
However, patients need to be carefully selected and informed, to allow for optimal balancing between the benefits and nonneglectable risks of severe toxicities. Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients' awareness about the possible side effects of PARPi.

|||||||||| Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Treatment of feline infectious peritonitis in cats with molnupiravir: clinical observations and outcomes for 54 cases. (Pubmed Central) - Jun 4, 2025
Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients' awareness about the possible side effects of PARPi. Molnupiravir demonstrated comparable survival outcomes to remdesivir/GS-441524 for treating FIP and serves as an accessible, effective option across various presentations, including ocular and neurologic forms.

|||||||||| Journal, PD(L)-1 Biomarker, IO biomarker: CLL cell-derived exosomes alter the immune and hematopoietic systems. (Pubmed Central) - Jun 3, 2025
CLL cell-derived exosomes inhibited hematopoietic progenitor proliferation, hindering the supportive effect of monocyte-derived fibrocytes. Together, our findings suggest that CLL cell-derived exosomes disrupt the immune and hematopoietic systems and contribute to disease progression in patients with CLL.

|||||||||| Journal: Postnatal cytomegalovirus infection in preterm infants at a tertiary hospital in Vietnam: Incidence, characteristics, and short-term outcomes. (Pubmed Central) - Jun 3, 2025
pCMV infection is common among preterm infants, and is associated with severe ROP, advanced BPD stages, and extended hospitalization. These findings highlight the need for early screening and tailored interventions to mitigate pCMVassociated complications among preterm populations.

|||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Clinical, Observational data, Journal, HEOR: Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study. (Pubmed Central) - Jun 3, 2025
These findings highlight the need for early screening and tailored interventions to mitigate pCMVassociated complications among preterm populations. D+/R- patients with severe leukopenia or neutropenia had a higher rate of outpatient consultations than those without episode (73.9% vs. 57.6%, p = 0.002), and a higher average number of consultations per patient (5.5

|||||||||| Journal: Fatal HLH in patients with X-linked lymphoproliferative disease 1 due to a novel variant in SH2D1A: case report. (Pubmed Central) - Jun 3, 2025
Our findings highlight the importance of early genetic diagnosis before EBV exposure to improve patient outcomes. The potential role of co-infections, including SARS-CoV-2, in triggering HLH in XLP1 remains an area for further investigation.

|||||||||| Melblez Kit (melphalan hepatic delivery system) / Delcath
Journal: An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. (Pubmed Central) - Jun 3, 2025
The potential role of co-infections, including SARS-CoV-2, in triggering HLH in XLP1 remains an area for further investigation. Treatment with Melphalan/HDS shows clinically meaningful efficacy and demonstrates a favorable benefit-risk profile in patients with unresectable mUM as compared to BAC.

|||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
P1 data, Journal: A phase 1 study of nilotinib in combination with paclitaxel in patients with advanced solid tumors. (Pubmed Central) - Jun 3, 2025
This study determined the MTD of this combination, demonstrated sustained cPRs in patients with AOGCT, and profiled molecular pharmacodynamic responses that will inform further mechanism of action studies. The rate of peripheral neuropathy suggests enhanced tolerability of this combination.

|||||||||| INCA033989 / Incyte
INCA33989 IS A NOVEL, FIRST IN CLASS, MUTANT CALRETICULIN-SPECIFIC MONOCLONAL ANTIBODY THAT DEMONSTRATES SAFETY AND EFFICACY IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) (Gold Hall) - Jun 3, 2025 - Abstract #EHA2025EHA_4723;
P1
INCA33989 monotherapy in ET patients who were resistant/intolerant to prior therapy was well-tolerated with no DLTs, and 98% of patients remain on treatment. Rapid and durable normalization of blood counts and reduction of mutCALR VAF was observed in most patients, and the potential for disease modification was evidenced by 25% of patients achieving an early PMR.

|||||||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
PHASE 2 STUDY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: REDIRECTT-1 (Gold Hall) - Jun 3, 2025 - Abstract #EHA2025EHA_4722;
P1/2
Tal + Tec led to a high ORR and deep, durable responses; efficacy exceeded standard therapies, including BsAb monotherapies, and was comparable to CAR-T therapies in pts with RRMM with EMD. No new safety signals were identified, including no exacerbated Tal or Tec AEs.

|||||||||| Retrospective data, Review, Journal: Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis. (Pubmed Central) - Jun 2, 2025
Despite these variations, BsAbs demonstrated an overall manageable safety profile, suggesting their viability as a treatment option in the relapsed/refractory setting. Standardized safety reporting and vigilant monitoring are essential to optimize their clinical use and improve patient outcomes.

|||||||||| Journal, Next-generation sequencing: Metagenomic Next-generation Sequencing Compared With Blood Culture as First-line Diagnostic Method for Bloodstream Infection in Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study. (Pubmed Central) - Jun 2, 2025
The findings suggest that the mNGS approach has excellent diagnostic performance for the first-line diagnosis of BSI in patients with FN. The study will promote early diagnosis and better management of the patients.

|||||||||| cyclophosphamide / Generic mfg.
Retrospective data, Journal: Cyclophosphamide for anticancer therapy-induced interstitial lung disease in the modern era: a retrospective cohort study. (Pubmed Central) - Jun 2, 2025
The differential responses based on drug category suggest tailored approaches to DIILD management may be warranted. These findings may contribute to optimizing the management of severe DIILD during cancer treatment.

||||||||||  Jiataile (sacituzumab tirumotecan) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy:  Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) (clinicaltrials.gov) -  Jun 2, 2025
P1, N=36, Active, not recruiting,  Sponsor: Merck Sharp & Dohme LLC
These findings may contribute to optimizing the management of severe DIILD during cancer treatment. Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2025 --> Jun 2026

|||||||||| Journal: Low-Risk Febrile Neutropenia Management: An Audit of Practice in a UK Cancer Center. (Pubmed Central) - Jun 1, 2025
Oncology nurses are key to standardizing FN risk assessment and advocating for equitable outpatient FN care. Addressing disparities in low-risk FN management may optimize healthcare resources and improve patient experience.

|||||||||| Journal: Febrile neutropenia management in high-risk neutropenic patients: a Narrative Review on Antibiotic Prophylaxis and empirical treatment. (Pubmed Central) - Jun 1, 2025
Carefully-designed, randomized, controlled trials providing large scale data which then can be analyzed with emerging artificial intelligence (AI) technologies are needed. The results from such trials may allow a better, data-driven approaches for management of FN.

|||||||||| P2a data, Journal: Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. (Pubmed Central) - May 31, 2025
P2
The results from such trials may allow a better, data-driven approaches for management of FN. Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen.

|||||||||| P3 data, Journal: TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial. (Pubmed Central) - May 31, 2025
P3
The modified FLOT/TFOX regimen significantly improved progression-free survival, overall survival, and objective response rate compared with FOLFOX in previously untreated patients with advanced HER2-negative gastric and gastro-oesophageal junction adenocarcinoma. The modified FLOT/TFOX regimen might represent a new first-line treatment option for patients eligible for this docetaxel triplet chemotherapy.

|||||||||| zidovudine / Generic mfg.
Retrospective data, Journal: Effects of maternal antiretroviral drugs in pregnancy on haematological and biochemical parameters in neonates exposed in utero. (Pubmed Central) - May 30, 2025
The modified FLOT/TFOX regimen might represent a new first-line treatment option for patients eligible for this docetaxel triplet chemotherapy. ART may cause side effects including anaemia, macrocytosis and neutropenia.MethodsIn a retrospective study conducted in a District General Hospital in the United Kingdom in 2024 using a historical cohort, we compared neonatal haemoglobin, mean corpuscular volume (MCV), reticulocyte, neutrophil and lymphocyte counts, alanine aminotransferase and bilirubin levels on the first day of life and at 6

||||||||||  CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov) -  May 30, 2025
P1/2, N=110, Recruiting,  Sponsor: Washington University School of Medicine
ART may cause side effects including anaemia, macrocytosis and neutropenia.MethodsIn a retrospective study conducted in a District General Hospital in the United Kingdom in 2024 using a historical cohort, we compared neonatal haemoglobin, mean corpuscular volume (MCV), reticulocyte, neutrophil and lymphocyte counts, alanine aminotransferase and bilirubin levels on the first day of life and at 6 Active, not recruiting --> Recruiting | N=62 --> 110 | Trial completion date: Nov 2025 --> Oct 2028 | Trial primary completion date: Nov 2025 --> Oct 2028

||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial initiation date:  Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) -  May 30, 2025
P2, N=40, Not yet recruiting,  Sponsor: Yeon Hee Park
Active, not recruiting --> Recruiting | N=62 --> 110 | Trial completion date: Nov 2025 --> Oct 2028 | Trial primary completion date: Nov 2025 --> Oct 2028 Initiation date: Jan 2025 --> Jun 2025

|||||||||| Journal: Phlegmonous Gastritis as the First Presentation of Acute Leukemia: A Case Report. (Pubmed Central) - May 30, 2025
This case highlights the importance of suspecting PG in severe abdominal pain and neutropenia. This will reduce the complications, mortality, and requirement for surgical intervention.

||||||||||  colchicine / Generic mfg.
Trial completion date, Trial primary completion date:  LEADER-PAD: Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk (clinicaltrials.gov) -  May 30, 2025
P3, N=6150, Recruiting,  Sponsor: Population Health Research Institute
This will reduce the complications, mortality, and requirement for surgical intervention. Trial completion date: Apr 2029 --> Dec 2029 | Trial primary completion date: Apr 2029 --> Dec 2029

|||||||||| Stivarga (regorafenib) / Bayer, irinotecan / Generic mfg.
P2 data, Journal: Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study. (Pubmed Central) - May 29, 2025
The study was stopped early because of limited efficacy and increased toxicities in the REGIRI arm, possibly due to drug interactions. No optimal sub-population that could benefit from a REGIRI regimen exposure was identified.



	Diseases Companies Products Productz Mechanisms of Action Sites